Develops and commercializes precision molecular diagnostics. Utilizes a proprietary molecular counting platform for highly sensitive DNA molecule detection. Now — the numbers.
This is an established company with proven profits.
If every debt were paid off today, $387.1M would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Sales are growing strongly for its sector.
The price is looking for direction — no strong breakout, no collapse.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 34% below its peak. The market has trimmed its expectations for the company.
Over the last 2 years, sales grew about 106% a year on average.
There is $496.0M in the vault; even if every debt were paid off, $387.1M would remain.
The company’s market value is 611 times its annual profit. Even a small disappointment could hit the price hard.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 34/100.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
On our five-subject report card, BLLN sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: BLLN is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (34/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the growth trend, the revenue breakdown.